Lymphoma  >>  dexamethasone  >>  Phase 4
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone / Generic mfg.
GDPML followed by MA in Patients with Newly Diagnosed Aggressive T Cell Lymphoma, ChiCTR-ONC-12002055: Gemcitabine, Cisplatin, Dexamethasone, Pegaspargase and Methotrexate (GDPML) followed by Methotrexate, Cytarabine (MA) In Patients with Newly Diagnosed Aggressive T Cell Lymphoma

Completed
4
30
 
Gemcitabine, Cisplatin, Dexamethasone, Pegaspargase and Methotrexate (GDPML) followed by Methotrexate, Cytarabine (MA)
Hematology Department of Peking Union Medical College Hospital; Hematology Department of Peking Union Medical College Hospital, Self funding
Aggressive T Cell Lymphoma
 
 
CTTNKTL-â…¢/â…£, NCT01501149: Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ

Unknown status
4
80
RoW
DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase), DDGP regiment, Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）, Modified SMILE regiment
Mingzhi Zhang, Second Hospital of Shanxi Medical University, Shanxi Province Cancer Hospital, Wuhan University, Wuhan TongJi Hospital, Wuhan Union Hospital, China, Qingdao University, Cancer Hospital of Guizhou Province, Xinyang Central Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Nasal and Nasal-type NK/T-cell Lymphoma
12/15
05/19
CTTNKTL-I/II, NCT01501136: Treatment of Natural Killer/T Cell Lymphoma-I/II

Unknown status
4
200
RoW
DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase), DDGP, chemotherapy, radiotherapy, VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）, VIPD, gemcitabine,pegaspargase,cisplatin,dexamethasone, cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna, Radiotherapy
Mingzhi Zhang, Second Hospital of Shanxi Medical University, Shanxi Province Cancer Hospital, Wuhan University, Wuhan TongJi Hospital, Wuhan Union Hospital, China, Qingdao University, Cancer Hospital of Guizhou Province, Xinyang Central Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Nasal and Nasal-type NK/T-cell Lymphoma
12/15
05/19
ChiCTR1800015640: A study for Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) Regimen followed by ASCT in the treatment of advanced-stage Extranodal NK/T cell lymphoma

Recruiting
4
37
 
Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) Regimen followed by ASCT
Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine; Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine, Project of Clinical Research， Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medcine
Nk/T cell lymphoma
 
 
NCT03071822: Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

Unknown status
4
50
RoW
cisplatin, ifosfamide, gemcitabine, L-asparaginase, etoposide, dexamethasone
The University of Hong Kong
Peripheral T Cell Lymphoma
07/21
02/22
RUE-DDGP, NCT04999878: A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen () in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.

Recruiting
4
30
RoW
Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum
Zhengzhou University
Hemophagocytic Syndrome, T/NK-Cell Lymphoma
06/23
06/24

Download Options